How Effective Are Bepreve Eye Drops in Treating Allergic Conjunctivitis?
March 22, 2011
ISTA Pharmaceuticals, Inc. today announced additional results from the Company’s BEPREVE(R) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies to treat allergic conjunctivitis.
Presented in poster sessions at the 2011 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Francisco, the results demonstrated that BEPREVE was statistically superior to placebo in reducing nonocular symptoms associated with allergic conjunctivitis.
Click here for the full press release.
Jump down to form below to submit your own comments